Justin Zelin, an analyst from BTIG, reiterated the Buy rating on ProKidney (PROK – Research Report). The associated price target is $6.00.

The REACT trial was a multicenter, double-blind, randomized, placebo-controlled, parallel-group, phase 3 study conducted at 74 sites in 15 countries across North America and Europe.

Between May 2010 and July 2014, a total of 700 patients were enrolled in the trial at 22 centers in Japan and were randomly assigned to the AF group (N=349) or the CF group (N=351).